Weilizhizhi is applying to list on the Hong Kong Stock Exchange, positioning itself as a leader in the development of next-generation tumor immunotherapy.
VTech plans to submit an application to the Hong Kong Stock Exchange.
Insider Sale: Director at $BGNE (BGNE) Sells 200 Shares
Bernstein Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
BeiGene's Four Drugs Included in China's Medical Insurance Catalog; Shares Jump 5%
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)
